Search

everythingexperts & clinicslearnfaqsresearchcommunity

for

Search:↓

Corticosteroids improved symptoms in a man with Cronkhite-Canada Syndrome.

This study found that topical application of carpronium chloride led to arteriolar vasodilation and increased blood flow in rat mesenteric arterioles, without affecting systemic blood pressure.

This study found that a new transdermal drug delivery system using globefish skin collagen peptides and dissolving microneedles effectively promoted hair regrowth in mice with androgenetic alopecia by reducing inflammation and enhancing vascularization.

This article reviews the use of platelet rich plasma in treating androgenetic alopecia and discusses the potential limitation of pain from injections, without presenting new clinical results.

This study found that an extract from Justicia procumbens may prevent hair loss in a mouse model of androgenic alopecia by enhancing hair follicle cell proliferation and improving hair characteristics.

This case report describes a 60-year-old woman with Cronkhite-Canada syndrome whose symptoms and polyposis improved following prednisolone therapy, but emphasizes the need for periodic digestive tract screening due to associated cancer risks.

This study found that PKCα activation in transgenic mice induces keratinocyte apoptosis and mediates neutrophilic skin inflammation via different pathways, suggesting potential mechanisms for cutaneous inflammatory diseases.

This study found that exposing dermal papilla cells to sub-lethal doses of colchicine releases histone H4, which inhibits cell growth and decreases alkaline phosphatase activity, potentially explaining colchicine-induced hair loss.

This study found that apocynin restored collagen production, reduced DNA damage and senescence, and protected skin stem cells from aging in UVB-exposed human keratinocytes.

In this study, 1% pimekrolimus cream was found to be more effective than 0.05% clobetasol propionate for treating active plaques in patients with alopecia areata.

In this study, topical application of Cyclosporin A on mice skin induced hair growth by transitioning follicles from telogen to anagen, but no effect was observed on cultured human hair follicles.

This study found that valproic acid may interfere with the leucine metabolic pathway by inhibiting 3-methylcrotonyl-CoA carboxylase and biotinidase, which could contribute to side effects like skin rash and hair loss in patients.

CCCA may be a fibroproliferative disorder, and anti-fibrotic therapies could help.

This article reviews the effectiveness of adrenal cortex compounds E and F in treating various connective tissue disorders and reports no new clinical findings.

In this study, researchers found that topical application of 3-β-methoxy-Δ18-oleanene (miliacin) in mice sped up the recovery of hair follicles damaged by cyclophosphamide, moving them into a new hair growth cycle more quickly compared to controls.

In this study, researchers found that isoproterenol, an adrenergic β2 receptor agonist, promoted hair growth and hair follicle stem cell proliferation in models of androgenetic alopecia by modulating the PI3K/AKT/β-Catenin pathway, suggesting a potential new therapeutic strategy for hair loss.

This case report suggests that crisaborole may be an effective alternative treatment for alopecia areata in pediatric patients, showing significant hair regrowth after two weeks in a 10-year-old girl.

This study reports on a 46-year-old patient with pseudopelades of Brocq, highlighting the effectiveness of early diagnosis and treatment in preventing atrophy and controlling hair loss, as positive clinical outcomes were noted after prescribed therapy.

In this study, the researchers report that a modified epimorphin-derived peptide shows potential for hair follicle regeneration, especially when used with 1% minoxidil in mice.

In this study, researchers highlighted that while oral valproate often causes hair loss, preliminary experiments with topical valproic acid solution suggest its potential for hair regeneration, potentially offering fewer side effects and reduced cost compared to existing treatments.

This study found that valproic acid is effective in controlling absence seizures and can improve other seizure types, but 20% of patients experience mostly transient adverse reactions.

This study found that combining 308-excimer phototherapy with intramuscular triamcinolone acetonide was effective and well tolerated for treating resistant alopecia totalis, showing a 90% overall response rate in the ten patients studied, with the best results observed in younger patients.

This study identified a novel mutation in the coproporphyrinogen oxidase gene, contributing to hereditary coproporphyria in a family, with decreased enzyme activity observed in the affected members.

This study observed that discontinuation rates due to side effects were similar for penicillamine and tiopronin among cystinuria patients, and switching to the alternative agent was beneficial for half of those experiencing issues.

In this report, a 19-year-old Japanese man experienced severe and prolonged urticarial reactions following treatment with diphenylcyclopropenone for alopecia universalis, emphasizing the need for caution with potent sensitizers.

In this study, oral collagen peptides increased certain gene expressions related to epidermis development and the hair cycle in hairless mice skin, suggesting potential links to hair health.

This study found that using a protease-triggered release system enabled effective delivery of a model drug deep within porcine hair follicles, suggesting a new approach for treating skin conditions.

This review discusses various treatments for pityriasis rubra pilaris, including vitamin A, methotrexate, and systemic steroids, reporting historical anecdotal evidence without new clinical results.

This study enrolled nine patients to investigate the effects of oral psoralen and ultraviolet A therapy plus oral prednisolone for treating alopecia areata.

This case report describes a 64-year-old man with advanced colorectal cancer developing cutaneous side effects from panitumumab, highlighting the importance of early diagnosis and treatment to improve quality of life and therapy continuation.